Why Consumers are Switching Providers and Payers - Solutions to Ease Turnover per Loren McCaghy

Why We Can’t Give Up on Value-Based Care | AHIP 2024

What Employers Are Requesting From Health Plans | AHIP 2024

SCAN Health Plan’s Karen Schulte Emphasizes Data & Health Equity in Customizing Benefits | AHIP 2024

Tailored Healthcare Solutions Through Segmentation Analysis | AHIP 2024

SCAN Health’s Sachin Jain: "We Must Critically Assess Ourselves to Simplify Healthcare"

Sachin Jain Calls for Leadership Overhaul to Simplify U.S. Healthcare System | AHIP 2024

Timothy Law: GLP-1 Drugs Changed the Paradigm in Weight Loss | AHIP 2024

Timothy Law: Coverage for GLP-1 Drugs for Obesity is Flux | AHIP 2024

Merith Basey, M.Sc., Executive Director, Patients for Affordable Drugs, AHIP 2024, part2

Merith Basey, M.Sc., Executive Director, Patients for Affordable Drugs | AHIP 2024

Surya Bhatt Presents Results of NOTUS Trial for COPD Treatment | 2024 ATS

Paul Kelly on the politics of drug prices

Paul Kelly on PBM reform and extension of Medicare telehealth flexibilities

Paul Kelly on prospects of PBM reform legislation passing the Senate

The Potential of ENV-101 in Treating Idiopathic Pulmonary Fibrosis and Cancer | 2024 ATS

These Programs Might Be Impacted by the Results of the Upcoming Presidential Election | ATS 2024

Ways Healthcare Differs Depending on the State an Immigrant Child Resides In | ATS 2024

The Healthcare Services Immigrant Children Need the Most | ATS 2024

Debra M. Boyer, M.D., Nationwide Children's Hospital, 2024 ATS International Conference

Specialty Pharmacies Drive Cost Savings in Value-Based Care | Asembia 2024

Sarah Butler & Lindsay Bealor Greenleaf, ADVI Health, 24 Asembia, discuss the 2024 election

Luke Greenwalt, MBA, VP, market access, IQVIA, on obesity drug market, Asembia 24

George Van Antwerp, MBA, Asembia 24, on GLP-1s for Weight Loss

Lockhart 1

Lockhart 2

George Van Antwerp, MBA, Deloitte, Asembia 24, on the Meaning of "Specialty Lite"

Luke Greenwalt, MBA, VP, market access, IQVIA, Asembia 24, on access to healthcare in the U.S.

Luke Greenwalt, MBA, VP, market access, IQVIA, at Asembia 2024, on drug launches

Lockhart 3